Graves' Disease A Comprehensive Guide for Clinicians
This indispensable volume is designed to facilitate the best possible physician–patient discussion on Graves’ disease by providing the most up-to-date evidence-based information in a clinically useful and patient-centric manner. Comprehensive and co
- PDF / 8,396,666 Bytes
- 347 Pages / 439.43 x 683.15 pts Page_size
- 72 Downloads / 249 Views
Graves’ Disease A Comprehensive Guide for Clinicians
123
Graves’ Disease
Rebecca S. Bahn Editor
Graves’ Disease A Comprehensive Guide for Clinicians
Editor Rebecca S. Bahn Professor of Medicine Mayo Clinic College of Medicine Division of Endocrinology and Metabolism Mayo Clinic Rochester, MN, USA
ISBN 978-1-4939-2533-9 ISBN 978-1-4939-2534-6 DOI 10.1007/978-1-4939-2534-6
(eBook)
Library of Congress Control Number: 2015935197 Springer New York Heidelberg Dordrecht London © Springer Science+Business Media New York 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer Science+Business Media LLC New York is part of Springer Science+Business Media (www.springer.com)
Preface
Graves’ disease combines the clinical symptoms and signs of hyperthyroidism, diffuse goiter, characteristic ocular findings, and less frequently unique dermatologic changes. The earliest descriptions of the triad in modern medical context can be found in writings by Caleb Perry [1], Robert Graves [2], and Carl von Basedow [3]. The eye disease is variously termed Graves’ ophthalmopathy or orbitopathy (GO), or simply thyroid eye disease (TED). Graves’ hyperthyroidism is mediated by autoantibody stimulation of the thyrotropin receptor on thyrocytes resulting in excess thyroid hormone production. The fundamental immunologic abnormalities leading to the production of these antibodies is complex and as yet incompletely understood, as is their relationship to the development of GO. Precise targeted therapy of the Graves’ disease syndrome will likely become available once pathogenic mechanisms are better understood. Until then treatment options for hyperthyroidism are limited to functional ablation of the thyroid gland using radioactive iodine or surgery, or to pharmacologic inhibition of thyroid hormonogenesis. Therapeutic options for GO are similarly limited to the targeting of disease manifestations, rather than basic mechanisms. Nevertheless, there have been a numbe
Data Loading...
